Skip to main content

Advertisement

SpringerLink
Log in

TNFα inhibitor biosimilar associated with polychondritis. A case-based review

  • Case Based Review
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Relapsing polychondritis (RP) is a rare autoimmune disease characterized by inflammation of the cartilage structures of the body with typical features of auricular chondritis, nasal and ocular inflammation, audio-vestibular damage, as well as respiratory tract manifestations. It is associated with several autoimmune diseases and many other disorders. Tumor necrosis factor alpha (TNFα) inhibitors treat many chronic inflammatory disorders. They have proven effective and relatively safe in many clinical trials and observational studies. However, several autoimmune phenomena and paradoxical inflammation have been described with TNFα inhibitors, among them RP. This report presents a 43-year-old man with psoriatic arthritis treated with ABP-501 (Amgevita), an adalimumab (ADA) biosimilar and who developed RP, 8 months after the initiation of the treatment. This, is the first report of RP development during TNFα inhibitors biosimilar. We concluded that rheumatologists dealing with patients treated with TNFα inhibitors (originators or biosimilars), should be aware of several paradoxical reactions which may emerge and RP, is one of them.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

Not applicable.

References

  1. Davidson A, Diamond B (2001) Autoimmune diseases. N Engl J Med 345(5):340–350. https://doi.org/10.1056/NEJM200108023450506

    Article  CAS  PubMed  Google Scholar 

  2. Sfikakis PP, Bournia VK, Sidiropoulos P et al (2017) Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. Clin Exp Rheumatol 35(4):579–585

    PubMed  Google Scholar 

  3. Drosos AA, Pelechas E, Kaltsonoudis E, Markatseli TE, Voulgari PV (2021) Biologic therapies and autoimmune phenomena. Mediterr J Rheumatol 32(2):96–103. https://doi.org/10.31138/mjr.32.2.96

    Article  PubMed  PubMed Central  Google Scholar 

  4. Drosos AA, Pelechas E, Voulgari PV (2022) Biological therapies: induced autoimmune adverse manifestations. Adv Pharmacoeridemiol Drug Saf https://doi.org/10.35248/2167-1052.22.11.264

  5. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A (2005) Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthr Rheum 52(8):2513–2518. https://doi.org/10.1002/art.21233

    Article  CAS  Google Scholar 

  6. Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA (2008) Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 67(4):567–570. https://doi.org/10.1136/ard.2007.075663

    Article  CAS  PubMed  Google Scholar 

  7. Skalkou A, Pelechas E, Voulgari PV, Drosos AA (2022) TNF-induced lupus a case-based review. Curr Rheumatol Rev 18(1):72–82. https://doi.org/10.2174/1573397117666211102094330

    Article  PubMed  Google Scholar 

  8. Exarchou SA, Voulgari PV, Markatseli TE, Zioga A, Drosos AA (2009) Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 38(5):328–331. https://doi.org/10.1080/03009740902922612

    Article  CAS  PubMed  Google Scholar 

  9. Hernández MV, Ruiz-Esquide V, Gómez-Caballero ME, Gómez-Puerta JA, Cañete JD, Sanmartí R (2011) Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists? Rheumatology (Oxford) 50(8):1523–1525. https://doi.org/10.1093/rheumatology/ker144

    Article  CAS  PubMed  Google Scholar 

  10. Pelechas E, Voulgari PV, Drosos AA (2018) ABP 501 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 18(3):317–322. https://doi.org/10.1080/14712598.2018.1430760

    Article  CAS  PubMed  Google Scholar 

  11. Rudwaleit M, van der Heijde D, Landewé R et al (2011) The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70(1):25–31. https://doi.org/10.1136/ard.2010.133645

    Article  CAS  PubMed  Google Scholar 

  12. McAdam LP, O’Hanlan MA, Bluestone R, Pearson CM (1976) Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 55(3):193–215

    Article  CAS  PubMed  Google Scholar 

  13. Gasparyan AY, Ayvazyan L, Blackmore H et al (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31(11):1409–1417. https://doi.org/10.1007/s00296-011-1999-3

    Article  PubMed  Google Scholar 

  14. Kingdon J, Roscamp J, Sangle S, D’Cruz D (2018) Relapsing polychondritis: a clinical review for rheumatologists. Rheumatology (Oxford) 57(9):1525–1532. https://doi.org/10.1093/rheumatology/kex406

    Article  PubMed  Google Scholar 

  15. Cantarini L, Vitale A, Brizi MG et al (2014) Diagnosis and classification of relapsing polychondritis. J Autoimmun 48–49:53–59. https://doi.org/10.1016/j.jaut.2014.01.026

    Article  CAS  PubMed  Google Scholar 

  16. Borgia F, Giuffrida R, Guarneri F, Cannavò SP (2018) Relapsing polychondritis: an updated review. Biomedicines 6(3):84. https://doi.org/10.3390/biomedicines6030084

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Pazirandeh M, Ziran BH, Khandelwal BK, Reynolds TL, Khan MA (1988) Relapsing polychondritis and spondyloarthropathies. J Rheumatol 15(4):630–632

    CAS  PubMed  Google Scholar 

  18. Bahiri R, Bzami F, Benbouazza K, Saoud B, Hajjaj-Hassouni N (2006) Relapsing polychondritis and ankylosing spondylitis in the same patient. Joint Bone Spine 73(4):482–484. https://doi.org/10.1016/j.jbspin.2005.12.011

    Article  PubMed  Google Scholar 

  19. Pelechas E, Papoudou-Bai A, Voulgari PV, Drosos AA (2021) Cutaneous autoimmune phenomena of the anti-TNFa biosimilars. Casebased review. Curr Rheumatol Rev 17(2):267–270. https://doi.org/10.2174/1573397116666201119151349

    Article  PubMed  Google Scholar 

  20. Pelechas E, Voulgari PV, Drosos AA (2022) TNFα inhibitor biosimilars associated with alopecia areata. Case-based review. Rheumatol Int 42(6):1113–1117. https://doi.org/10.1007/s00296-022-05129-w

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Arvaniti Chrysa for her secretarial assistance.

Author information

Authors and Affiliations

  1. Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece

    Aliki I. Venetsanopoulou, Paraskevi V. Voulgari & Alexandros A. Drosos

  2. Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Ioannina, Greece

    Alexandros A. Drosos

Authors
  1. Aliki I. Venetsanopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paraskevi V. Voulgari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexandros A. Drosos
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed equally to this manuscript. AIV drafting of the manuscript and search of the literature, PVV reviewed critically and corrected the manuscript. AAD captured the idea and critically reviewed the manuscript. Contributions statement: all authors approved the final manuscript as submitted and agreed to be accountable for all aspects of the work.

Corresponding author

Correspondence to Alexandros A. Drosos.

Ethics declarations

Competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Venetsanopoulou, A.I., Voulgari, P.V. & Drosos, A.A. TNFα inhibitor biosimilar associated with polychondritis. A case-based review. Rheumatol Int 43, 1751–1754 (2023). https://doi.org/10.1007/s00296-023-05364-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-023-05364-9

Keywords

Search

Navigation